<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107416</url>
  </required_header>
  <id_info>
    <org_study_id>17-141</org_study_id>
    <nct_id>NCT03107416</nct_id>
  </id_info>
  <brief_title>Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells</brief_title>
  <official_title>Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of Bumetanide , at different doses to find
      out what effects, if any, it has on people who undergo tumor TAE as part of their regular
      care. Bumetanide is a commonly used medication to reduce the amount of water in the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">April 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) (phase I)</measure>
    <time_frame>1 year</time_frame>
    <description>Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>estimate the local tumor progression (LTP) rates (phase II)</measure>
    <time_frame>1 year</time_frame>
    <description>After the last first stage patient has three months followup, 6-month LTP will be estimated using Kaplan-Meier methods. If the one-sided 90% lower confidence bound is less than 40% the study will stop. Otherwise 12 more patients will be enrolled for a total of 30. At the end of the study 12-month LTP will be estimated using competing risk (cumulative incidence) methods.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Bumetanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic artery embolization (HAE)</intervention_name>
    <description>The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.</description>
    <arm_group_label>Bumetanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide</intervention_name>
    <description>Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.</description>
    <arm_group_label>Bumetanide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnoses of HCC according to European Association for the Study of
             Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy
             will be allowed.

               -  Any virus status accepted (e.g. Hepatitis C etc.)

               -  Any prior liver treatment

          -  Patients within unresectable HCC

          -  At least 18 years old

          -  ECOG performance status 0 or 1

          -  Radiographically measurable disease per mRECIST 1.1

          -  Meets standard of care to undergo embolization

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Documented hypersensitivity to bumetanide or sulfonamides

          -  Patients with resectable HCC

          -  High risk for post-embolization hepatic failure:

             °Child's C cirrhosis

             °&gt; 80% liver involvement by tumor

          -  Contraindication to angiography/embolization including:

               -  Patients cannot receive contrast:

               -  Severe allergic reaction to contrast despite premedication

               -  Poor renal function not on dialysis

               -  Other, based on judgment of the investigator

          -  ECOG score 2

          -  Main portal vein tumor thrombus

          -  BCLC D = patients with distant metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hooman Yarmohammadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hooman Yarmohammadi, MD</last_name>
    <phone>212-639-2234</phone>
    <email>yarmohah@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen T. Brown, MD</last_name>
    <phone>212-639-5882</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hooman Yarmohammadi, MD</last_name>
      <phone>212-639-2234</phone>
    </contact>
    <contact_backup>
      <last_name>Karen T. Brown, MD</last_name>
      <phone>212-639-5882</phone>
    </contact_backup>
    <investigator>
      <last_name>Hooman Yarmohammadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bumetanide</keyword>
  <keyword>Diuretic</keyword>
  <keyword>Transarterial Embolization (TAE)</keyword>
  <keyword>17-141</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

